← Leaderboards
Radhakrishnan P Iyer
Spring Bank Technologies, Inc.
$6,780,629
Attributed
$6,780,629
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $901.5K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$6,780,629 · 3
By mechanism
R01$3,801,133 · 1
U01$2,379,496 · 1
R43$600,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Antiviral Agents”
- Constance Ann Benson · University Of California, San Diego$209,152,068
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$120,325,769
- Judith S. Currier · University Of California Los Angeles$102,391,456
- Beth Baseler · Leidos Biomedical Research, Inc.$83,440,795
- Sharon A Nachman · Johns Hopkins University$77,262,665
- John Damon Chodera · Sloan-Kettering Inst Can Research$58,660,403
Research focus
Antiviral AgentsOralAcuteToxic EffectIndexingLiverMouse ModelPharmaceutical PreparationsProdrugsSolutionsSafetyIn VivoPre-ClinicalIn VitroPharmacodynamicsDrug ResistanceNucleotide AnalogAnti-Hepatitis CNucleoside AnalogAffectCollaborationsNational Institute Of Allergy And Infectious DiseaseLiver InfectionMedical
Grant awards (12)
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent$901,490
R01 · FY2015 · AI · contact PI
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent$856,160
R01 · FY2014 · AI · contact PI
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent$687,555
R01 · FY2013 · AI · contact PI
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent$590,928
R01 · FY2012 · AI · contact PI
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent$765,000
R01 · FY2011 · AI · contact PI
DINUCLEOTIDE ISOMER AS A NOVEL ANTIVIRAL$300,000
R43 · FY2010 · AI · contact PI
DINUCLEOTIDE ISOMER AS A NOVEL ANTIVIRAL$300,000
R43 · FY2009 · AI · contact PI
THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENT$610,629
U01 · FY2007 · AI · contact PI
THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENT$500,129
U01 · FY2006 · AI · contact PI
THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENT$527,243
U01 · FY2005 · AI
THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENT$476,545
U01 · FY2004 · AI
THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENT$264,950
U01 · FY2003 · AI